Musculoskeletal

Sanofi bags rights to Revolution’s SHP2 cancer drug Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drugs against SHP2. The partners plan to move small molecule SHP2 inhibitor RMC-4630 into the clinic later this year. Sanofi has also committed to covering the R&D costs of the joint SHP2 program and paying out up to $500 million in development and commercial milestones. RMC-4630, is due to enter a first in human trial. The drug could target a range of indications, but Sanofi has singled out one disease in its discussions of the collaboration. Pfizer, Lilly tout positive tanezumab data, but safety questions remain Pfizer and...